Oxford University Press

SHERPA: Yellow

People

  1. Cheung
    Cheung
  2. Kramer
    Kramer
  3. Zanzonico
    Zanzonico
  4. Kushner
    Kushner
  5. Humm
    Humm
  6. Pandit-Taskar
    Pandit-Taskar
  7. Souweidane
    Souweidane
  8. Khakoo
    Khakoo
  9. Modak
    Modak
  10. Wolden
    Wolden

Groups

  1. Neuroblastoma Service (40)
  2. Pediatrics, Department of (40)
  3. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (25)
  4. GSK Faculty (25)
  5. Tow Center for Developmental Oncology (TCDO) (25)
  6. Neuro-Oncology Service (21)
  7. Radiology, Department of (18)
  8. Survivorship Research (18)
  9. Medical Physics (15)
  10. Center for Hematologic Malignancies (14)
Search Within
  1. "Neuroblastoma Service"
Formats
  1. Meeting Abstract (35)
  2. Journal Article (5)
Groups
  1. Neuroblastoma Service (40)
  2. Pediatrics, Department of (40)
  3. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (25)
  4. GSK Faculty (25)
  5. Tow Center for Developmental Oncology (TCDO) (25)
  6. Neuro-Oncology Service (21)

More Groups

People
  1. Nai-Kong Cheung (25)
  2. Kim Kramer (17)
  3. Pat Zanzonico (15)
  4. Brian Kushner (14)
  5. John Humm (13)
  6. Mark Souweidane (13)

More People

Years
  1. 2022 (3)
  2. 2021 (2)
  3. 2020 (4)
  4. 2019 (4)
  5. 2018 (5)
  6. 2017 (3)

More Years

Publications
  1. Neuro-Oncology (31)
  2. Annals of Oncology (7)
  3. JNCI: Journal of the National Cancer Institute (2)

Results (40)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Naxitamab treatment for relapsed or refractory high-risk neuroblastoma: Outcomes from the first prespecified analyses of the Pivotal 201 Trial
    Meeting Abstract

    Mora, J.; Bear, M.; Chan, G.; Morgenstern, D. A.; Nysom, K.; Tornøe, K.; Sørensen, P. S.; Kushner, B.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)
    Journal Article

    Desai, A. V.; Robinson, G. W.; Gauvain, K.; Basu, E. M.; Macy, M. E.; Maese, L.; Whipple, N. S.; Sabnis, A. J.; Foster, J. H.; Shusterman, S.; more...
    Neuro-Oncology (2022)

    Fulltext@MSK | Save
  • Long-term survival from a phase 1 doseescalation trial using convection-enhanced delivery (CED) of radioimmunotherapeutic (124)I-omburtamab for treatment of diffuse intrinsic pontine glioma (DIPG)
    Meeting Abstract

    Souweidane, M. M.; Kramer, K.; Pandit-Tasker, N.; Haque, S.; Zanzonico, P.; Carrasquillo, J.; Lyashchenko, S. K.; Thakur, S. B.; Khakoo, Y.; Dunkel, I. J.; more...
    Neuro-Oncology (2022)

    Fulltext@MSK | Save
  • Assessment of corticosteroid premedication for patients treated with the humanized GD2-binding monoclonal antibody naxitamab
    Meeting Abstract

    Mora, J.; Bear, M.; Chan, G.; Morgenstern, D. A.; Nysom, K.; Tornøe, K.; Hindsberger, C.; Kushner, B.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Naxitamab for the treatment of refractory/relapsed high-risk neuroblastoma (HR NB): Updated efficacy and safety data from the international, multicenter phase II trial 201
    Meeting Abstract

    Mora, J.; Bear, M.; Chan, G.; Morgenstern, D. A.; Nysom, K.; Tornøe, K.; Losic, N.; Kushner, B.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Entrectinib in recurrent or refractory solid tumors including primary CNS tumors: Updated data in children and adolescents
    Meeting Abstract

    Robinson, G.; Desai, A.; Basu, E.; Foster, J.; Gauvain, K.; Sabnis, A.; Shusterman, S.; Macy, M.; Mease, L.; Yoon, J.; more...
    Neuro-Oncology (2020)

    Fulltext@MSK | Save
  • Efficacy and updated safety results from pivotal phase II trial 201 of naxitamab (Hu3F8): A humanized GD2-targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB)
    Meeting Abstract

    Mora, J.; Chan, G. C.; Morgenstern, D. A.; Nysom, K.; Bear, M.; Worsaae Dalby, L.; Lisby, S.; Kushner, B. H.
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Pivotal trial 201 data on outpatient administration of naxitamab (Hu3F8), a humanized GD2 targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB)
    Meeting Abstract

    Morgenstern, D. A.; Mora, J.; Chan, G. C.; Nysom, K.; Bear, M.; Worsaae Dalby, L.; Lisby, S.; Kushner, B. H.
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Characterization of on-target adverse events caused by TRK inhibitor therapy
    Journal Article

    Liu, D.; Flory, J.; Lin, A.; Offin, M.; Falcon, C. J.; Murciano-Goroff, Y. R.; Rosen, E.; Guo, R.; Basu, E.; Li, B. T.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Entrectinib in children and adolescents with recurrent or refractory solid tumors including primary CNS tumors
    Meeting Abstract

    Robinson, G.; Desai, A.; Gauvain, K.; Basu, E.; Dorris, K.; Maese, L.; Sabnis, A.; Foster, J.; Shusterman, S.; Yoon, J.; more...
    Neuro-Oncology (2019)

    Fulltext@MSK | Save